Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Change in Accured Expenses (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Change in Accured Expenses for 12 consecutive years, with -$3.5 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Accured Expenses fell 296.48% year-over-year to -$3.5 million; the TTM value through Mar 2026 reached -$98000.0, down 127.57%, while the annual FY2025 figure was $5.4 million, 3333.7% up from the prior year.
  • Change in Accured Expenses hit -$3.5 million in Q1 2026 for Crescent Biopharma, down from -$1.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.7 million in Q2 2025 and bottomed at -$3.5 million in Q1 2026.
  • Average Change in Accured Expenses over 5 years is -$377348.3, with a median of -$198895.0 recorded in 2023.
  • Year-over-year, Change in Accured Expenses plummeted 850.29% in 2022 and then skyrocketed 233.49% in 2025.
  • Crescent Biopharma's Change in Accured Expenses stood at $1.2 million in 2022, then tumbled by 107.27% to -$85820.0 in 2023, then crashed by 1435.44% to -$1.3 million in 2024, then rose by 19.63% to -$1.1 million in 2025, then crashed by 226.35% to -$3.5 million in 2026.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$3.5 million, -$1.1 million, and $2.7 million for Q1 2026, Q4 2025, and Q2 2025 respectively.